This study states that In the United States, influenza is typically diagnosed during an in-person healthcare visit and if antiviral treatment is prescribed, a subsequent visit to a pharmacy is required. This multi-step process may lead to delays in receipt of antivirals and potentially exposes other individuals in clinics and pharmacies to influenza. Since antiviral therapy is most effective when started within 48 hours of symptom onset, reducing delays to treatment initiation may improve outcomes in treated persons.1-3 Baloxavir is an oral FDA-approved antiviral for early treatment of uncomplicated influenza in individuals aged 12 years and older. The long half-life of baloxavir allows a single treatment dose in contrast to five twice-daily doses of oseltamivir. Moreover, baloxavir treatment is associated with shorter duration of influenza virus detection compared with oseltamivir or placebo. Households, particularly those with young children, play a key role in seasonal influenza epidemics because the frequency and intensity of contacts among household members are greater than in the broader community.5 Prior studies have shown that young children are important contributors to the introduction and transmission of influenza in households.6, 7 Therefore, households represent an important setting to study influenza intervention strategies.
Reference link- https://onlinelibrary.wiley.com/doi/10.1111/irv.12859